FPD/AML is associated with germline mutations in RUNX1, a master transcription factor regulator of hematopoiesis and blood vessel development, most commonly small indels or point mutations that can lead to haploinsufficiency or dominant negative effects (Latger-Cannard et al., 2016). The gene discussed is RUNX1; the disease is acute myeloid leukemia.